StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $3.33 | $3.25 | -2.40% | 1.1M |
| 05-18 | $3.26 | $3.17 | -2.76% | 1.4M |
| 05-19 | $3.13 | $3.14 | +0.32% | 0.9M |
| 05-20 | $3.16 | $3.24 | +2.53% | 0.7M |
| 05-21 | $3.22 | $3.34 | +3.73% | 0.3M |
No sell-side coverage available for ADCT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $20.03M | $51.24M | $35.49M | $17.40M |
Operating Income | $-25.25M | $-103.58M | $-72.61M | $-28.46M |
Net Income | $-32.97M | $-136.21M | $-95.25M | $-38.60M |
EPS (Diluted) | $-0.21 | $-1.14 | $-0.86 | $-0.36 |
Total Assets | $291.50M | $289.76M | $321.56M | $272.54M |
Total Liabilities | $507.87M | $527.94M | $520.75M | $510.76M |
Cash & Equivalents | $231.01M | $234.74M | $264.56M | $194.70M |
Free Cash Flow OCF − CapEx | $-29.74M | $-110.31M | $-80.69M | $-56.60M |
Shares Outstanding | 127.17M | 112.63M | 112.50M | 99.18M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.